Takeda Pharmaceutical (TAK) Short term Debt (2018 - 2026)

Takeda Pharmaceutical's Short term Debt history runs 9 years deep, the most recent figure standing at $900.5 million for Q1 2026.

• On a quarterly basis, Short term Debt fell 74.97% year-over-year to $900.5 million in Q1 2026; TTM through Mar 2026 was $900.5 million, a 74.97% decrease from a year earlier, with the FY2026 full-year figure at $938.2 million, down 73.97% from the prior year.
• Short term Debt eased to $900.5 million in Q1 2026 per TAK's latest filing, from $27.7 billion in the prior quarter.
• Across five years, Short term Debt topped out at $33.4 billion in Q2 2022 and bottomed at $900.5 million in Q1 2026.
• The 5-year median for Short term Debt is $29.0 billion (2023), against an average of $21.9 billion.
• Across the five-year window, Short term Debt surged 46.26% in 2023 and plunged 74.97% in 2026, its largest moves.
• Year by year, Short term Debt stood at $27.7 billion in 2022, then grew by 4.83% to $29.0 billion in 2023, then rose by 6.53% to $30.9 billion in 2024, then slipped by 10.34% to $27.7 billion in 2025, then slumped by 96.75% to $900.5 million in 2026.
• Per Business Quant, the three latest TAK Short term Debt figures stand at $900.5 million (Q1 2026), $27.7 billion (Q4 2025), and $29.5 billion (Q3 2025).